Stocktoria
ABBOTT LABORATORIES ABT
NYSE · XNYS · stock · Pharmaceutical Preparations · website · IPO 1937-03-01
ABBOTT LABORATORIES financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $44.3B | $42.0B | $40.1B | $43.7B | $43.1B |
| R&D expense | $2.9B | $2.8B | $2.7B | $2.9B | $2.7B |
| SG&A expense | $12.3B | $11.7B | $10.9B | $11.2B | $11.3B |
| Operating income | $8.1B | $6.8B | $6.5B | $8.4B | $8.4B |
| Interest expense | — | — | $637.0M | $558.0M | $533.0M |
| Income tax | $1.9B | -$6.4B | $941.0M | $1.4B | $1.1B |
| Net income | $6.5B | $13.4B | $5.7B | $6.9B | $7.1B |
| EPS (diluted) | $3.72 | $7.64 | $3.26 | $3.91 | $3.94 |
| Operating cash flow | $9.6B | $8.6B | $7.3B | $9.6B | $10.5B |
| Free cash flow | $7.4B | $6.4B | $5.1B | $7.8B | $8.6B |
| Cash & equivalents | $8.5B | $7.6B | $6.9B | $9.9B | $9.8B |
| Inventory | $6.5B | $6.2B | $6.6B | $6.2B | $5.2B |
| Total assets | $86.7B | $81.4B | $73.2B | $74.4B | $75.2B |
| Shareholders' equity | $52.8B | $47.9B | $38.8B | $36.9B | $36.0B |
Source: SEC EDGAR filings · CIK 0000001800 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.